FDA Inspection 1023509 — Biocryst Pharmaceuticals, Inc.
The FDA completed an inspection of Biocryst Pharmaceuticals, Inc. on May 5, 2017 in Durham, NC. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- May 5, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Durham, NC (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)